References
1-Bukiri H, Volkmann ER. Current advances in the treatment of systemic
sclerosis. Curr Opin Pharmacol. 2022 Jun;64:102211. doi:
10.1016/j.coph.2022.102211. Epub 2022 Apr 18. PMID: 35447517; PMCID:
PMC9466985.
2-Smeeta
Gajendra, Richa
Gupta, Ritu
Gupta, and Lalit
Kumar. Coexistence of scleroderma with multiple
myeloma: a rare association.
BMJ Case
Rep. 2013. doi: 10.1136/bcr-2013-200639.PMCID: PMC3794227.PMID: 24022902
3- Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune
manifestations in patients with multiple myeloma and monoclonal
gammopathy of undetermined significance. BBA Clin. 2016 May 25;6:12-8.
doi: 10.1016/j.bbacli.2016.05.004. PMID: 27331023; PMCID: PMC4900299.
4-Frank van den Hoogen, etal.2013 classification criteria for Systenic
Slerosis. Arhtritis & Rheumatism 2013.Volume65.N.11.PP:2737-2747.
5- Korting GW, Gilfrich HJ, Meyer zum Buschenfelde KH. Scleroderma
adultorum and multiple myeloma. Arch Dermatol
Forsch 1974;2013:379–85.
6- Doyle JA, Connolly SM, Hoagland HC. Hematologic disease in
scleroderma syndromes. Acta Derm Venereol 1985;2013:521–5
7-Ohta A, Uitto J, Oikarinen AI, et al. Paraproteinemia in patients with
scleroderma. Clinical findings and serum effects on skin fibroblasts in
vitro. J Am Acad Dermatol 1987;2013:96–107.
8-Hodak E, Tamir R, David M, et al. Scleroderma adultorum associated
with IgG-kappa multiple myeloma—a case report . Clin Exp
Dermatol 1988;2013:271–4.
9-Rimon D, Lurie M, Storch S, et al. Cardiomyopathy and multiple
myeloma. Complications of scleroderma adultorum. Arch Intern
Med 1988;2013:551–3
10-Salisbury JA, Shallcross H, Leigh IM. Scleroderma of Buschke
associated with multiple myeloma. Clin Exp
Dermatol 1988;2013:269–70
11- Nakanishi H, Takehara K, Soma Y, et al. Atypical scleroderma
associated with multiple myeloma. Dermatologica 1989;2013:176–8
12-Schmidt KT, Gattuso P, Messmore H, et al. Scleroderma and smoldering
myeloma. J Am Acad Dermatol 1992;2013:319–21
13- Pujol JA, Bueno M, Fuertes MA, et al. Improvement of scleroderma
associated with IgA multiple myeloma alter chemotherapy. Clin Exp
Dermatol 1995;2013:149–52.
14-Valente L, Velho GC, Farinha F, et al. Scleroderma, acanthosis
nigricans and IgA/kappa multiple myeloma. Ann Dermatol
Venereol 1997;2013:537–9.
15-Bachleitner-Hofmann T, Machold K, Knobler R, et al. Marked and
sustained improvement of systemic sclerosis following polychemotherapy
for coexistent multiple myeloma. Clin Exp
Rheumatol 2002;2013:85–8
16-Colovic M, Jurisic V, Bila J, et al. FGF-R3 and OPG expression in
patient with multiple myeloma following systemic sclerosis: case report
and review of the literature. Int J Hematol 2011;2013:228–31.
17- Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A. New Era in Systemic
Sclerosis Treatment: Recently Approved Therapeutics. J Clin Med. 2022
Aug 8;11(15):4631. doi: 10.3390/jcm11154631. PMID: 35956246; PMCID:
PMC9369903.
18- Oliver SJ, Kaplan G. Reduced fibrosis and normalization of skin
structure in scleroderma patients treated with
thalidomide. Arthritis Rheum 1999;2013:S187.